Knight therapeutics enters into exclusive license agreement with amneal pharmaceuticals for ipx203

Montreal, jan. 25, 2024 (globe newswire) -- knight therapeutics inc. (tsx: gud) ("knight"), a pan-american (ex-usa) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with amneal pharmaceuticals, inc. (nasdaq: amrx) ("amneal"), granting knight the exclusive rights to seek regulatory approval and commercialize ipx203 in canada and latin america. ipx203 is a novel, oral formulation of carbidopa/levodopa (cd/ld) extended-release capsules designed for the treatment of parkinson's disease. financial terms of the agreement were not disclosed.
AMRX Ratings Summary
AMRX Quant Ranking